AtriCure
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2000-11-01
- Employees
- 1.2K
- Market Cap
- -
- Website
- http://www.atricure.com
- Introduction
AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.
Clinical Trials
35
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (29 trials with phase data)• Click on a phase to view related trials
BoxX-NoAF Clinical Trial
- Conditions
- Post Operative Atrial FibrillationAtrial Fibrillation, Postoperative
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- AtriCure, Inc.
- Target Recruit Count
- 960
- Registration Number
- NCT06989775
- Locations
- 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
Cryo NerVe Block Extremity AmputatioN RegIStry for Post Operative and pHantom Limb Pain
- Conditions
- AmputationAmputation of Lower LimbAmputation of Upper LimbAmputation, Limb LossAmputation, Traumatic/SurgeryCryo Analgesia
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- AtriCure, Inc.
- Target Recruit Count
- 2000
- Registration Number
- NCT06908538
- Locations
- 🇺🇸
Elliot Hospital, Manchester, New Hampshire, United States
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
- Conditions
- Ischemic StrokeSystemic Embolism
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- AtriCure, Inc.
- Target Recruit Count
- 6573
- Registration Number
- NCT05478304
- Locations
- 🇺🇸
Heart Center Research / Huntsville Hospital, Huntsville, Alabama, United States
🇺🇸HonorHealth Shea Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸St. Bernard's Heart & Vascular, Jonesboro, Arkansas, United States
CONVERGE Post-Approval Study (PAS)
- Conditions
- Chronic Atrial Fibrillation
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- AtriCure, Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT05393180
- Locations
- 🇺🇸
Eisenhower Medical Center, Rancho Mirage, California, United States
🇺🇸Bridgeport Hospital System, Bridgeport, Connecticut, United States
🇺🇸Orlando Health, Orlando, Florida, United States
HEAL-IST IDE Trial
- Conditions
- Inappropriate Sinus Tachycardia
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AtriCure, Inc.
- Target Recruit Count
- 142
- Registration Number
- NCT05280093
- Locations
- 🇺🇸
Loma Linda University Health, Loma Linda, California, United States
🇺🇸Sequoia Hospital, Redwood City, California, United States
🇺🇸Stanford University, Redwood City, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
AtriCure's EPi-Sense System Receives FDA Approval for Long-Standing Persistent Afib Treatment
• AtriCure's EPi-Sense system has gained FDA approval for treating long-standing persistent atrial fibrillation (Afib), offering a new option for a challenging patient population. • The Converge clinical trial demonstrated the superiority of Hybrid AF therapy using the EPi-Sense system compared to endocardial catheter ablation alone. • Hybrid AF therapy showed a 29% absolute improvement in efficacy at 12 months and a 35% absolute improvement at 18 months compared to catheter ablation. • The EPi-Sense system improves electrophysiology lab efficiency by reducing endocardial ablation times by over 40 minutes, enhancing patient throughput.